Locate Bio Limited

Locate Bio is trying to improve orthopedic surgery outcomes with proprietary regenerative materials based on advanced polymer technology, controlled drug release, and advanced ceramic technologies. T

Quentin Blackford, CEO, iRhythm "In 2022, expect remote patient monitoring to expand as patients and providers rely more heavily on actionable insights from uninterrupted health data. Reactive diagnos

Locate Bio has closed a funding round worth approximately $14m (£10m), intended to further advance Locate’s line of regenerative orthobiologics products. The financing round, announced on 3 September